Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
Keywords: Breast cancer; Central nervous system (CNS) metastases; HER2; Small-molecule tyrosine kinase inhibitors; Lapatinib; Neratinib; Afatinib; Tucatinib;